Narwhal Capital Management Acquires 3,845 Shares of Eli Lilly and Company $LLY

Key Points

• Narwhal Capital Management has increased its holdings in Eli Lilly and Company by 17.9% during the second quarter, bringing their total shares to 25,376, valued at approximately $19.78 million.
• The stock of Eli Lilly has a current market capitalization of $800.28 billion, with shares trading between a 12-month low of $623.78 and a high of $937.00.
• Eli Lilly exceeded analysts' earnings expectations, reporting an EPS of $6.31 in the last quarter, significantly higher than the forecasted $5.59.

Narwhal Capital Management increased its holdings in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 17.9% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 25,376 shares of the company's stock after buying an additional 3,845 shares during the period. Eli Lilly and Company accounts for about 1.6% of Narwhal Capital Management's investment portfolio, making the stock its 14th biggest holding. Narwhal Capital Management's holdings in Eli Lilly and Company were worth $19,781,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of LLY. PNC Financial Services Group Inc. increased its stake in Eli Lilly and Company by 97.5% in the first quarter. PNC Financial Services Group Inc. now owns 101,305,650 shares of the company's stock valued at $83,669,349,000 after purchasing an additional 50,002,551 shares in the last quarter. Nuveen LLC bought a new stake in Eli Lilly and Company in the first quarter valued at approximately $4,613,912,000. Vanguard Group Inc. increased its stake in Eli Lilly and Company by 6.7% in the first quarter. Vanguard Group Inc. now owns 79,224,392 shares of the company's stock valued at $65,432,218,000 after purchasing an additional 4,975,395 shares in the last quarter. Cohen Investment Advisors LLC increased its stake in Eli Lilly and Company by 7,975.5% in the first quarter. Cohen Investment Advisors LLC now owns 783,651 shares of the company's stock valued at $647,225,000 after purchasing an additional 773,947 shares in the last quarter. Finally, Assenagon Asset Management S.A. increased its stake in Eli Lilly and Company by 106.8% in the second quarter. Assenagon Asset Management S.A. now owns 1,481,031 shares of the company's stock valued at $1,154,508,000 after purchasing an additional 765,010 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY opened at $845.55 on Thursday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $937.00. The firm has a fifty day simple moving average of $738.69 and a 200 day simple moving average of $766.57. The stock has a market capitalization of $800.28 billion, a price-to-earnings ratio of 55.26, a PEG ratio of 1.18 and a beta of 0.47. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $6.31 EPS for the quarter, topping the consensus estimate of $5.59 by $0.72. Eli Lilly and Company had a net margin of 25.91% and a return on equity of 92.72%. The business had revenue of $15.56 billion during the quarter, compared to analysts' expectations of $14.40 billion. During the same quarter in the prior year, the company posted $3.92 earnings per share. The firm's revenue was up 37.6% on a year-over-year basis. Eli Lilly and Company has set its FY 2025 guidance at 21.750-23.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 EPS for the current fiscal year.

Insider Buying and Selling at Eli Lilly and Company

In other news, CEO David A. Ricks purchased 1,632 shares of the company's stock in a transaction on Tuesday, August 12th. The shares were purchased at an average cost of $644.77 per share, with a total value of $1,052,264.64. Following the completion of the transaction, the chief executive officer owned 546,601 shares of the company's stock, valued at $352,431,926.77. The trade was a 0.30% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Jamere Jackson purchased 200 shares of the company's stock in a transaction on Friday, August 8th. The shares were purchased at an average cost of $639.56 per share, for a total transaction of $127,912.00. Following the completion of the transaction, the director directly owned 9,402 shares of the company's stock, valued at approximately $6,013,143.12. This represents a 2.17% increase in their position. The disclosure for this purchase can be found here. Insiders have acquired a total of 4,514 shares of company stock valued at $2,894,841 in the last three months. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several brokerages have commented on LLY. Hsbc Global Res raised shares of Eli Lilly and Company from a "moderate sell" rating to a "hold" rating in a research note on Wednesday, August 27th. Deutsche Bank Aktiengesellschaft reduced their price target on shares of Eli Lilly and Company from $1,010.00 to $900.00 and set a "buy" rating for the company in a report on Monday, August 11th. Morgan Stanley reduced their price target on shares of Eli Lilly and Company from $1,028.00 to $1,023.00 and set an "overweight" rating for the company in a report on Friday, October 3rd. Daiwa Capital Markets cut shares of Eli Lilly and Company from an "outperform" rating to a "neutral" rating and set a $700.00 price target for the company. in a report on Sunday, August 17th. Finally, Guggenheim upped their price target on shares of Eli Lilly and Company from $875.00 to $948.00 and gave the company a "buy" rating in a report on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating and ten have issued a Hold rating to the company. Based on data from MarketBeat, Eli Lilly and Company currently has a consensus rating of "Moderate Buy" and an average price target of $943.00.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.